GeneralBullishBlockonomi · 4h ago6/10
📰
Natera (NTRA) Stock Soars 7% Following Japanese Regulatory Milestone for Signatera
Natera's stock surged 7.67% following Japan's regulatory approval of Signatera for colorectal cancer minimal residual disease (MRD) testing, marking the first authorized test of this kind in the country. This milestone represents significant market expansion for the company's liquid biopsy technology into a major Asian healthcare market.